{
    "xml": "<topic id=\"PHP81607\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/prilotekal\" basename=\"prilotekal\" title=\"Prilotekal\">\n<title>Prilotekal<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP83030\" outputclass=\"indicationsAndDose\" rev=\"1.16\" parent=\"/clinical-medicinal-product-information/prilotekal\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Spinal anaesthesia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intrathecal injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Usual dose 40&#8211;60&#8239;mg (max. per dose 80&#8239;mg), dose may need to be reduced in elderly or debilitated patients, or in late pregnancy.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP83046\" outputclass=\"nationalFunding\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/prilotekal\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intrathecal</ph> use</p>\n<p>The <i>Scottish Medicines Consortium</i> has advised (December 2010) that prilocaine 2% hyperbaric solution for injection (<i>Prilotekal</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for use in spinal anaesthesia in ambulatory surgery settings.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81607",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/prilotekal",
    "basename": "prilotekal",
    "title": "Prilotekal",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Spinal anaesthesia",
                        "html": "Spinal anaesthesia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intrathecal injection"
                    ],
                    "textContent": "By intrathecal injection",
                    "html": "By intrathecal injection"
                },
                "adult": [
                    {
                        "textContent": "Usual dose 40&#8211;60 mg (max. per dose 80 mg), dose may need to be reduced in elderly or debilitated patients, or in late pregnancy.",
                        "html": "<p>Usual dose 40&#8211;60&#8239;mg (max. per dose 80&#8239;mg), dose may need to be reduced in elderly or debilitated patients, or in late pregnancy.</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "With intrathecal use The Scottish Medicines Consortium has advised (December 2010) that prilocaine 2% hyperbaric solution for injection (Prilotekal ) is accepted for restricted use within NHS Scotland for use in spinal anaesthesia in ambulatory surgery settings.",
                "html": "<p outputclass=\"specificity\">With <ph outputclass=\"route\">intrathecal</ph> use</p> <p>The <i>Scottish Medicines Consortium</i> has advised (December 2010) that prilocaine 2% hyperbaric solution for injection (<i>Prilotekal</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for use in spinal anaesthesia in ambulatory surgery settings.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}